UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1759-1767

2001

Volltextzugriff (PDF)

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

The American heart journal, 2003-10, Vol.146 (4), p.591-604

2003

Volltextzugriff (PDF)

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

The New England journal of medicine, 1999-01, Vol.340 (3), p.190-195

1999

Volltextzugriff (PDF)

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis

Journal of rheumatology, 2002-08, Vol.29 (8), p.1623

2002

Volltextzugriff (PDF)

152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents

CNS spectrums, 2020-04, Vol.25 (2), p.297-297

2020

Volltextzugriff (PDF)

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

Circulation (New York, N.Y.), 2001-11, Vol.104 (19), p.2280-2288

2001

Volltextzugriff (PDF)

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization

Endocrinology (Philadelphia), 2002-03, Vol.143 (3), p.998-1007

2002

Volltextzugriff (PDF)

Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial

JAMA network open, 2021-10, Vol.4 (10), p.e2129397-e2129397

2021

Volltextzugriff (PDF)

Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial

JAMA network open, 2021-10, Vol.4 (10), p.e2128204-e2128204

2021

Volltextzugriff (PDF)

Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study

Movement disorders clinical practice (Hoboken, N.J.), 2023-09, Vol.10 (9), p.1388-1398

2023

Volltextzugriff (PDF)

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids

The Journal of pharmacology and experimental therapeutics, 1999-05, Vol.289 (2), p.735

1999

Volltextzugriff (PDF)

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers

Journal of clinical pharmacology, 2000-10, Vol.40 (10), p.1109-1120

2000

Volltextzugriff (PDF)

Renal Effects of COX-2-Selective Inhibitors

American journal of nephrology, 2001-01, Vol.21 (1), p.1-15

2001

Volltextzugriff (PDF)

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children

Clinical pharmacology and therapeutics, 2001-07, Vol.70 (1), p.91-98

2001

Volltextzugriff (PDF)

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: A randomized controlled trial

Cancer, 2002-06, Vol.94 (11), p.3032-3041

2002

Volltextzugriff (PDF)

The Lancet and advertorials

The Lancet (British edition), 2009, Vol.373 (9668), p.1005-1005

2009

Volltextzugriff (PDF)

Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis

Journal of bone and mineral research, 1997-10, Vol.12 (10), p.1700-1707

1997

Volltextzugriff (PDF)

Montelukast Dose Selection in 6- to 14-Year-Olds: Comparison of Single-Dose Pharmacokinetics in Children and Adults

Journal of clinical pharmacology, 1999-08, Vol.39 (8), p.786-793

1999

Volltextzugriff (PDF)

Effects of Etoricoxib and Comparator Nonsteroidal Anti-Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet

Journal of clinical pharmacology, 2007-12, Vol.47 (12), p.1521-1531

2007

Volltextzugriff (PDF)

Studies of the oral bioavailability of alendronate

Clinical pharmacology and therapeutics, 1995-09, Vol.58 (3), p.288-298

1995

Volltextzugriff (PDF)

Efficacy and safety of rofecoxib in patients with chronic low back pain: Results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials

Spine (Philadelphia, Pa. 1976), 2003-05, Vol.28 (9), p.851-859

2003

Volltextzugriff (PDF)

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females

Pharmaceutical research, 1996-03, Vol.13 (3), p.445-448

1996

Volltextzugriff (PDF)

Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity

Journal of clinical pharmacology, 1999-12, Vol.39 (12), p.1212-1220

1999

Volltextzugriff (PDF)

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

Gastroenterology (New York, N.Y. 1943), 2001-03, Vol.120 (4), p.867-873

2001

Volltextzugriff (PDF)

The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

Clinical pharmacology and therapeutics, 2000-12, Vol.68 (6), p.626-636

2000

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(106)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(109)

Sprache

Englisch
(109)
Japanisch
(22)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(65)
Life Sciences & Biomedicine
(64)
Biological And Medical Sciences
(58)
Humans
(57)
Medical Sciences
(55)
Male
(47)
Pharmacology. Drug Treatments
(44)
Female
(35)
Adult
(33)
Double-Blind Method
(30)
Middle Aged
(25)
Pharmacology & Pharmacy
(23)
Animals
(20)
Aged
(17)
Bones, Joints And Connective Tissue. Antiinflammatory Agents
(15)
Dose-Response Relationship, Drug
(15)
Sulfones
(15)
Cross-Over Studies
(14)
Endocrinology & Metabolism
(13)
Cyclooxygenase 2
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis

152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization

Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial

Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial

Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids

Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers

Renal Effects of COX-2-Selective Inhibitors

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: A randomized controlled trial

The Lancet and advertorials

Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis

Montelukast Dose Selection in 6- to 14-Year-Olds: Comparison of Single-Dose Pharmacokinetics in Children and Adults

Effects of Etoricoxib and Comparator Nonsteroidal Anti-Inflammatory Drugs on Urinary Sodium Excretion, Blood Pressure, and Other Renal Function Indicators in Elderly Subjects Consuming a Controlled Sodium Diet

Studies of the oral bioavailability of alendronate

Efficacy and safety of rofecoxib in patients with chronic low back pain: Results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females

Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production

The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin

Suchergebnisse filtern